The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

“Price is not a rationale for dispensing a compounded medication, but the fact is, a lot of patients were able to afford the compounded versions of tirzepatide, and they’re likely not going to ...

Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...

Rhythm Pharmaceuticals (RYTM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...